Anti-thrombotic Ticagrelor have disappeared, but no news of generic benefit has been heard.

Since the expiration of material patents in November last year, six pharmaceutical companies, including Chong Kun Dang, have registered their benefits, but pharmaceutical companies that have obtained generic exclusivity or later approved have been hesitant to register their benefits. This is because manufacturing costs are high and marketability is insufficient.

According to the industry on the 13th, the general exclusivity period of Ticagrelor's generic will end on the 20th.No pharmaceutical company has applied for benefits on the premise of sales since that day.

Ticagrelor's origi